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Abstract.  The  non-steroidal  anti  inflammatory  drugs  represent  one  of  the  most  commonly  detected 
compounds  in  sewage  treatment  plant  (STP)  effluent  and  surface  water  with  scarce  information 
concerning  possible  ecotoxicological  risks.  As  in  mammals,  COX  has  been  shown  to  play  a  role  in 
reproduction in fish. Since studies on human breast cancer cells showed that COXs-inhibitors decreased 
aromatase  messenger  ribonucleic  acid  (mRNA)  expression  at  the  transcriptional  level  we  tested  the 
effects of supplementation of COX2-inhibitors (etodolac and etoricoxib) in the diet of fry tilapia on growth 
rate  and  mortality  during  the  crucial  period  of  sexual  differentiation.  Highlight  on  etoricoxib 
pharmacokinetics was carried out by determination of etoricoxib in fish feces using reversed-phase High 
Performance Liquid Chromatography (RF-HPLC) with Evaporative Light Scattering and Photo Diode array 
detector (ELSD-PDA  system).  At  an  age  of  8  days  post-hatched,  30  genetically  mixed  population  of 
Oreochromis niloticus larvae were stocked in duplicate, into 45 L aquariums in a closed system for six 
months. Treatments included 5 different experimental diets including, respectively, 0.5% etodolac, 1% 
etodolac, 2% etodolac, 0.5% etoricoxib, and 1% etoricoxib concentrations and one standard diet serving 
as control with two repeats for each group from 0.5% groups of diets. Fish were fed experimental diets 
for 8 weeks and were changed to control diet after. Another experiment was conducted using 10 adults 
mixed population stocked in triplicate in a closed system and treated as above. Growth rates (GR) were 
significantly  affected  with  the  highest  growth  rate  obtained  with  the  0.5%  etodolac.  However,  no 
increase or decrease in growth was observed in mixed adults population. GR increased with increasing 
concentrations with the highest GR in the aquarium treated with 2% etodolac, followed by 1% etodolac, 
but 1% etoricoxib showed a decreased GR compared to standard which could indicates a toxic potential 
toward  fish  at  this  concentration.  No  etoricoxib  peak  was  detected  on  HPLC  in  feces  samples  which 
reflected,  that,  it  was  well  absorbed  by  tilapias,  extensively  metabolized  with  no  unchanged  fraction 
excreted, or may undergo enter hepatic circulation, increasing further its toxic potential. No mortality 
was observed in adults mixed population. Mortality rates were 3.7% with 0.5% etodolac, 10% with 0.5% 
etoricoxib,  30%  with  1%  etodolac,  37%with  1%etoricoxib,  and  50%  with  2%  etodolac  treatments, 
respectively. It is clear evident that even administration of high concentrations of these drugs was well 
tolerated by fish. 
Key Words: Etodolac, etoricoxib, COX2-inhibitors, growth rates, mortality. 
 
Resumen. Los  antiinflamatorios  no  esteroideos  representan  uno  de  los  más  comúnmente  detectados 
compuestos en agua residual y agua superficial con escasa información relativa a los posibles riesgos 
ecotoxicológicos. Como en los mamíferos, Ciclooxigenasa COX es importante en la reproducción de los 
peces. Ya que los estudios en las células cancerosas humanas de mama demuestran que Ciclooxigenasa, 
inhibidores de la (COX) disminuyen la expresión del ácido ribonucleico ARN mensajero del aromatasa 
(ARNm) a nivel transcripcional, hemos probado los efectos de la suplementación de COX2-inhibidores 
(etodolaco y etoricoxib)en la dieta de la Tilapia sobre tasa de crecimiento, mortalidad durante el período 
crucial de diferenciación sexual. Determinación de etoricoxib en las heces de los peces utilizando fase-
invertido deCromatografía líquida de alto rendimiento (RF-HPLC) con ELSD-PD Adetector, fue llevada a 
cabo.  A  la  edad  de  8  dias  30  Mezcla genética  de  Oreochromis  niloticus  larvas  fueron  sembradas  por 
duplicado  en  45  L  acuarios  en  un  sistema  cerrado  durante  6  meses.  Los  tratamientos  incluian  5 
diferentes  dietas  experimentales  incluyendo  0,5%  etodolac,  1%  etodolaco,  2%  etodolac,  0,5% 
etoricoxib,  1%  etoricoxib  concentraciones  y  una  dieta  estándar  que  actúa  como  control  con  dos 
repeticiones para cada grupo de 0,5% grupos de dietas. Peces se alimentaron con dietas experimentales 
durante 8 semanas y cambiaron a la dieta control después. Otro experimento se llevó a cabo utilizando 
10  mezcla  de  adultos  sembradas  por  triplicado  en  un  sistema  cerrado  y,  tratadas  como  en  el  caso 
anterior. Tasas de crecimiento (GR) fueron significativamente afectadas con la mayor GR obtenida con el AACL Bioflux, 2011, Volume 4, Issue 5. 
http://www.bioflux.com.ro/aacl 
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0,5% etodolaco. Sin embargo, ningún aumento o disminución del crecimiento en población mixta adulta 
fue observada. GR aumentó con las crecientes concentraciones con la mayor GR en los acuarios tratados 
con  2%  etodolaco  seguida  de  1%  etodolaco,  pero  1%  etoricoxib  mostró  una  tasa  de  crecimiento 
disminuyó  en  comparación  con  el  estándar  que  indica  un  potencial  tóxico  para  los  peces  en  esta 
concentración.  Ningún  pico  de  etoricoxib  fue  detectada  por  HPLC  en  muestras  de  heces  fecales 
reflejando,  que,  se  absorbe  bien  por  el  tilapia,  extensamente  metabolizado  con  ninguna  fracción 
excretada inalterada, o puede someterse a entrar circulación hepática, aumentando aún más su potencial 
tóxico. No se observó mortalidad en población mixta de adultos. Las tasas de mortalidad fueron de 3,7% 
con 0,5% etodolaco, 10% con 0,5% etoricoxib, 30% con 1% etodolaco, 37% con 1% etoricoxib, y 50% 
con  2%  etodolaco  tratamientos,  respectivamente.  Es  evidente  que  administración  de  altas 
concentraciones fue bien tolerado por los peces. 
Palabras Clave: Etodolaco, etoricoxib, COX2-inhibidores, tasa de crecimiento, mortalidad. 
 
 
Introduction. Prostaglandins are biologically active derivatives of arachidonic acid and 
other  polyunsaturated  fatty  acids  that  are  released  from  membrane  phospholipids  by 
phospholipase  A2.  Prostaglandin  G/H  endoperoxide  synthase,  also  known  as 
cyclooxygenase is a key enzyme that catalyzes the conversion of arachidonic acid (ArA) 
to prostaglandins. When ArA is released from cell membranes by phospholipases mainly 
PLA2, it can be metabolized by prostaglandin G/H synthase. Prostaglandin G/H synthase 
is a membrane bound protein in the endoplasmatic reticulum of prostaglandin forming 
cells.  The  cyclooxygenase  (COX)  component  catalyses  the  oxidation  of  the  fatty  acid 
arachidonic acid (ArA, 20:4n-6) to the intermediate prostaglandin G2 (PGG2), which is 
rapidly  converted  into  PGs  (PGE2,  PGD2,  PGF2)  and  thromboxanes  (Simmons  et  al 
2004). Prostaglandins play a physiological significance and role in intracellular signaling 
in mammals (Cha et al 2005). In teleosts, they have been reported to be produced in the 
ovaries (Goetz et al 1991). Non steroidal anti-inflammatory drugs (NSAIDs), speciﬁcally 
COX-2 inhibitors, are known to inhibit ovulation in mammals (Gaytan et al 2006). As in 
mammals, COX has been shown to play a role in reproduction in fish. In the Atlantic 
croaker Micropogonias undulates (Linnaeus, 1766) COX pathways may play a role in the 
maturation of ovarian follicles and ovulation through prostaglandin formation (Patino et al 
2003). Results from the European sea bass Dicentrarchus labrax (Linnaeus, 1758) also 
indicate a similar role for prostaglandins in ovulation, with indomethacin inhibiting follicle 
maturation (Sorbera et al 2001). In the Japanese medaka Oryzias latipes (Temminck & 
Schlegel, 1846), exposure to low chronic levels of ibuprofen causes altered reproduction 
by decreasing the number of spawning events but increasing the number of eggs per 
spawning  event  (Flippin  et  al  2007).  In  an  earlier  study  using  non-selective  COX- 
inhibitors ibuprofen and diclofenac we showed no significant differences in growth rate 
(GR)  of  20  genetically  females  (XX)  of  Oreochromis  niloticus  (Linnaeus,  1758)  fry 
following treatment with 1% diclofenac, 5% diclofenac, and 5% ibuprofen, but 7% in the 
control group, 36% in the 1% diclofenac group, 17% in the 0.5% ibuprofen group, and 
22.2% in the 0.5% diclofenac group, respectively, never produced egg during the entire 
experimental period (Al-Qutob & Nashashibi 2009).  
The main goal of our study is to predict the effect of etodolac, a non-selective COX-
1 inhibitor with preferential COX-2 selectivity, and etoricoxib, a selective COX-2 inhibitor 
on growth during the crucial period of sexual differentiation. It is well known that there 
are differences in male vs female growth rates in Oreochromis species (Palada-de Vera & 
Eknath  1993;  Toguyeni  et  al  1997).  Monosex  production  or  even  incomplete  female 
prevents reproduction and therefore feed energy could be diverted into growth instead of 
production  of  unwanted  juvenile  fish  (Kwon  et  al  2001).  Brueggemeier  et  al  (1999) 
pointed  to  linear  dependence  between  aromatase  gene  (CYP  19)  expression  and 
expression  of  COX-2  in  mammary  carcinoma.  Cyclooxygenase  inhibitors  suppress 
aromatase expression and activity in breast cancer cells (Diaz-Cruz et al 2005) and since 
fish  posses  both  COX-1  and  COX-2  forms  and  both  are  widely  expressed  during 
development  with  both  isoforms  genetically  and  functionally  homologous  to  their 
mammalian orthologs (Grosser et al 2002; Mocuţa et al 2010), we tested the hypothesis 
of  possible  cyclooxygenase  inhibition  during  the  crucial  period  that  may  modulate 
aromatase activity, thus altering sexual differentiation.   
On  the  other  hand,  human  and  veterinary  pharmaceuticals  have  been  shown  to 
occur in considerably high amounts in sewage treatment plant (STP) effluent and surface AACL Bioflux, 2011, Volume 4, Issue 5. 
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water,  with  the  non-steroidal  anti  inflammatory  drugs  representing  one  of  the  most 
commonly detected compounds (Metcalfe et al 2003). Information concerning possible 
ecotoxicological  risks  of  these  substances  is  rather  scarce.  So  far  there  are  no  data 
available on their possible effects in fish after prolonged exposure. Thus, highlight on 
etoricoxib pharmacokinetics was carried out by determination of etoricoxib in fish feces 
samples using reversed-phase High Performance Liquid Chromatography (RF-HPLC) with 
Evaporative Light Scattering and Photo Diode array detector (HPLC-ELSD-PDA system).  
 
Material  and  Method.  The  study  was  carried  out  at  the  Aquaculture  Research 
Laboratory, in AL-Quds University, Jerusalem from 15th of November 2010 till 15th of 
May 2011. A warm water recirculation system consisting of a 24 aquaria, with capacity ≈ 
45 L each one was used for the study. Tap water from municipality was used for fish 
rearing. The experimental aquaria were housed indoor. Daily, quarter of the water was 
renewed  from  each  aquarium  in  order  to  maintain  optimum  water  quality  and  better 
hygiene. The flow rate of water was maintained at 0.5 L/min. All the aquaria were kept 
on  80  cm  high  platform  to  facilitate  better  observation  and  easy  maintenance.  Water 
temperature was maintained at 28 ± 1ºC. A constant photoperiod of 12 h light and 12 h 
dark was maintained throughout the experimental period. The water in the header tank 
was  aerated  by  an  air  stone  and  the  rates  of  water  flow  were  adjusted  to  maintain 
oxygen saturation above 60%. Total nitrogen ammonia was always less than 3mgL
−1. 
The water quality parameters in the system were monitored by doing water analysis. 
Genetically  mixed  population  of  tilapia  fry  aged  8  days  post-hatched  ≈  400  fry  were 
produced through the indirect approach of producing mixed sex fish (Piferrer 2001). 
Commercial feed was used as the control diet. Feed composition is shown in Table 
1. Etodolac and etoricoxib were purchased from Sigma and Alderich products. 
 
Table 1  
Feed composition and treatment concentrations 
 
Treatment  Composition  Concentration 
Control  91.8% DryMatter (OM) 
43.5% Crude protein 
10.9% Crude lipid 
13.0% Crude Ash 
18.7Kj Gross energy 
 
Etodolac    0.5%, 1%, 2% 
Etoricoxib    0.5%, 1% 
 
At an age of 8 days post–hatched 30 genetically mixed population of O. niloticus larvae 
were stocked in duplicate, into aquariums each with a capacity of ≈ 45 L at aquatic and 
aquaculture  lab,  where  the  study  was  conducted.  Treatments  included  5  different 
experimental diets and one standard diet serving as control with two repeats for each 
group from 0.5 % groups of diets. All aquariums in the experiment were disconnected 
from the recirculation system in order to avoid cross- contamination. The test diets were 
prepared  by  mixing  600mg  of  etodolac  with  120  g,  60  g,  30  g  commercial  feed,  to 
achieve 0.5% etodolac, 1% etodolac, 2% etodolac concentrations, respectively; the same 
process  was  done  to  the  etoricoxib  by  mixing  90mg  of  etoricoxib  with  18  g,  9  g 
commercial  feed,  also  to  achieve  0.5%  etoricoxib,  1%  etoricoxib  concentrations, 
respectively. Feeding started on the same day of stocking and fish were fed once daily. 
Feed was made into pellets crushed into smaller sizes and spread on the water surface 
slowly by hand. Feed was adjusted according to fish weight. They were fed 10% of their 
weight during the 8th week of the experiment with etodolac and etoricoxib, after this 
period they were fed 5% of their body weight and all diets were changed to control diet. 
Fish were weighted every week and counted in each aquarium to determine survival 
rate during 8 weeks period. Individual fish in each aquarium was weighted to the nearest 
0.1 g using a digital scale. The growth rate (GR) was determined using linear regression: 
yt = a + bxt, where yt is the average total weight (g) of the fishes at time t and a is the AACL Bioflux, 2011, Volume 4, Issue 5. 
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average weight (g) of fishes at the start of the experiment. Growth performance and diet 
nutrient utilization were analyzed in term of percent body weight gain (BWG), growth 
rate, feed conversion ratio (FCR), feed conversion efficiency (FCE), specific growth rate 
(SGR). BWG = 100* (final body weight – initial body weight)∕initial body weight. FCR = 
the weight of the feed fed to the fish along the study period∕live body weight gain. FCE = 
fresh body mass gain∕the weight of the feed fed to the fish along the study period. SGR 
(%) = 100* [ln (final body weight)-ln (initial body weight)]∕no. of days. 
 
Experiments done for fish growth rate 
 
Experiment  number  (1):  Mixed  population  of  adults  Nile  tilapia  treated  with  etodolac 
0.5% and etoricoxib 0.5% at age more than 2 month: nine aquariums were chosen for 
the  experiment  from  the  recirculating  system  after  being  separated  to  prevent  cross 
contamination. They were divided into three different groups and distributed randomly in 
all  side  of  the  system  to  achieve  the  same  condition  for  each  group.  These  groups 
included  three  for  standard  population  without  treatment,  three  with  etodolac  0.5% 
treatment,  and  three  for  etoricoxib  0.5%  treatment.  Ten  fish  were  stocked  in  each 
aquarium, the diet was given to fish in each aquarium once daily as 10% of the fish 
weight. Fish were weighted in each aquarium weekly and counted in each aquarium to 
determine survival rate during 8 weeks period. The 10% amount of diet given during the 
new week was calculated. 
Experiment number (2): Mixed population of Nile tilapia treated with etodolac 0.5% and 
etoricoxib 0.5% at age of 8 days: Thirty fry fish were stocked in each aquarium, at age of 
8 days, with duplicate aquariums for each group of etodolac 0.5%, etoricoxib 0.5%, and 
standard. The same procedure was done as in experiment one.  
Experiment  number  (3):  mixed  population  of  Nile  tilapia  treated  with  etodolac  1%, 
etoricoxib 1% and etodolac 2% at age of 8 days: Thirty fish at age of 8 days post hatch 
were  stocked  in  three  aquariums  in  duplicate,  one  for  each  group  of  etodolac  1%, 
etoricoxib  1%,  and  standard.  Only  20  fish  were  stocked  in  2%  etodolac  duplicate 
aquarium, and they were all treated in the same way as the previous experiments (1 and 
2).  
 
Determination of etoricoxib in fish feces by HPLC. Four months age Nile tilapia were 
separated  in  one  aquarium  from  the  recirculating  system  and  given  diet  with  1% 
etoricoxib. Feces samples each with triplicate were collected after half an hour, 1 hour, 2 
hours, 3 hours, 4 hours, and 24 hours, respectively. Etoricoxib determination was carried 
out using reversed-phase HPLC with 2424 Evaporative Light Scattering and 996 Photo 
Diode  Array  detector  (HPLC–ELSD-PDA,  Water  Alliance  HPLC  system)  in  the  analysis 
center lab in Al Quds University. A simple reverse phase HPLC method was developed for 
estimation of etoricoxib in fish feces. The method was carried out on a Water X bridge 5 
Mm,  C8  column  with  a  mobile  phase  consisting  of  methanol:  acetonitrile:  phosphate 
buffer 3.5 (40:20:40 V/V) at flow rate of 1ml/min, detection was carried out at 210nm 
and the retention time of etoricoxib was 4.18 min. Linearity was investigated by serially 
diluting the stock solution to give concentration in the range 20-100 mg/1000ml (ppm). 
An aliquot (10 ml) was injected using a mixture methanol: acetonitrile: phosphate buffer 
pH 3.5 (40:20:40) V/V as mobile phase. Calibration curve was obtained by plotting the 
peak area versus concentration.  
 
Results and Discussion 
 
Growth performance parameters. The growth performance parameters (BWG, FCR, 
FCE, SGR, and GR) of O. niloticus fed with etodolac (non-selective COX-1 inhibitor with 
preferential COX-2 selectivity) and etoricoxib (selective COX-2 inhibitor), respectively, 
were significantly affected by COX-2 inhibitors administration with Nile tilapia diet, with 
the  highest  growth  obtained  with  the  0.5%  etodolac,  followed  by  etoricoxib  0.5%, 
followed by untreated sample (Table 2, Figure 1). No significant differences were found in 
the average weights and growth rates (p>0.05), in mixed population adult Nile tilapia. In AACL Bioflux, 2011, Volume 4, Issue 5. 
http://www.bioflux.com.ro/aacl 
 
695 
humans, NSAIDs are reported to cause a gradual weight gain attributed to the effect of 
medication  itself or due to its effect on other factors (Boullata & Armenti 2004). Our 
discussion will be based on three points of view, the aromatase theory, the interfering 
with thyroid axis and the modulated gastrointestinal blood flow (GBF).                              
 
                                                                                                                     Table  2 
Body weight gain and other important growth parameters in mixed population Nile tilapia 
treated with etodolac 0.5% and etoricoxib 0.5% at age of 8 days 
 
 
Figure 1. Growth rate of mixed population of Nile tilapia treated with 0.5% etodolac and 0.5% 
etoricoxib mixed with food at age of 8 days (std1 - standard 1%, std2 - standard 2%, etd1 - 
etodolac 1%, etd2 - etodolac 2%, eto1 - etoricoxib 1%, eto2 - etoricoxib2%). 
 
Our  observation  of  significant  differences  in  growth  rates  of  mixed  fry  Nile  tilapia 
compared  to  adult  mixed  population  following  exposure  to  0.5%  etodolac  and  0.5% 
etoricoxib at this early stage indicates that Cox inhibitors could alter aromatase activity 
needed for proper sexual development and reproduction as mentioned earlier. An earlier 
study conducted in our lab showed alteration in reproduction following exposure to non 
selective Cox inhibitors (Al-Qutob & Nashashibi 2009). 
We propose that alteration of aromatase activity at the transcriptional level by the 
COX-inhibitors decreases the rate of aromatization which alters E2 (estrogen) levels. Low 
E2 release the feedback inhibition on gonadotropins producing high follicle stimulating 
hormone (FSH) levels that inhibits ovulation, since it is present in the blood of immature 
fish and levels increase during the vitellogenic phase but should decline towards follicular 
maturation and spawning (Kawauchi et al 1989). FSH release in female tilapia is under 
the  control  of  the  hypothalamic  decapeptide  Gonadotropin  releasing  hormone  (GnRH) 
and the feedback inhibition loop at the gonadal-pituitary-axis (Aizen et al 2007; Yaron et 
al 2003). 
The  somatic  growth  of  teleosts  is  controlled  by  the  growth  axis  consisted  of 
hypothalamus–pituitary–liver,  i.e.  the  GH/IGF-I  axis.  Growth  hormone  (GH)  released 
from the pituitary gland binds to its receptor and stimulates insulin-like growth factor-I 
(IGF-I) synthesis and secretion from the liver and other sites, evoking biological actions 
through IGF receptors (Butler & LeRoith 2001). However, the modulation patterns in the 
  BWG (g)  FCR  FCE  SGR (%) 
Standard 1  600  0.333  3.00  3.97 
Standard 2  692  0.312  3.20  4.22 
etodolac 1  1023  0.304  3.28  4.93 
etodolac 2  1033  0.303  3.29  4.95 
etoricoxib 1  875  0.311  3.211  4.64 
etoricoxib 2  536  0.326  3.06  3.77 AACL Bioflux, 2011, Volume 4, Issue 5. 
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axis are not a basic point to point linear regulation and feedback, but rather are a kind of 
multifactorial and multiregulational manner, which makes up a regulation network of GH 
synthesis  and  secretion  in  fish.  In  the  hypothalamus,  a  number  of  neuro  endocrine 
factors  directly  act  on  somatotropes,  including  pituitary  adenylate  cyclase-activating 
peptide  (PACAP),  GH-releasing  hormone  (GHRH),  gonadotropin-releasing  hormone 
(GnRH), Neuropeptide Y (NPY), and somatostatin (SS). In addition, these neuroendocrine 
factors have interactions controlling GH secretion and are also affected by some of the 
peripheral  factors.  Gonadotropin  (GtH)  released  from  the  anterior  pituitary  regulating 
reproductive functions, interacts with GH at multiple levels to respectively modulate the 
functions  of the gonadotrophic and somatotrophic axes. In mammals, at the pituitary 
level,  transcripts  of  GH  receptors  and  GH-binding  sites  are  observed  to  appear  in 
gonadotrophs, and the stimulatory actions of GnRH on Luteinizing hormone (LH) and FSH 
release are inhibited by GH immune neutralization, suggesting that endogenous GH may 
act in a para-crine manner regulating gonadotroph functions. Similarly, GH release is also 
under the influence of the gonadotrophic axis, especially via the release of sex steroids. 
In fact according to our hypothesis which is previously stated the high FSH could 
increase growth hormone secretion by somatotrophs. Zhou et al (2004) proposed a novel 
mechanism regulating GH release and synthesis in fish where by the local interactions 
between gonadotrophs and somatotrophs may form an intrapituitary feedback loop for 
regulating  GH  release  and  synthesis.  In  this  model,  gonadotropin  released  from 
gonadotrophs induces GH release and GH production in neighboring somatotrophs. GH 
secretion  maintains  somatotroph  sensitivity  to  GtH  stimulation,  and  simultaneously, 
inhibits basal GtH release in gonadotrophs. In tilapia, the somatotrophs are located in the 
proximal pars distalis (PPD) forming a palisade around the nerve ramifications; the GtH I 
(FSH-like) gonadotrophs are adjacent but slightly peripheral to them, whereas the GtH II 
(LH-like) gonadotrophs outlay these cells. Paracrine interactions also exist between the 
gonadotrophs and somatotrophs in the tilapia pituitary (Melamed et al 1999). No direct 
effects of gonadal steroids on expression of the tilapia GH gene were reported. Although 
they  did  appear  to  increase  the  sensitivity  of  the  somatotrophs  to  some  of  the 
hypothalamic GH-releasing hormones, the effects of testosterone could be mimicked by 
estradiol (E2), but not the non aromatizable 11-ketotesoterone, as the testosterone is 
aromatized before eliciting these effects (Melamed et al 1999). 
Thyroid  hormones  are  thought  to  play  a  permissive  role  in  the  growth  process, 
potentiating the effects of other anabolic hormones, most notably growth hormone. The 
main actions of TH in fish appear to involve regulation of growth, early development, 
metamorphosis and aspects of reproduction (Brown et al 2004). Thyroid status itself is 
one of the most potent regulators of iodothyronine deiodinase expression. The study of 
Mol et al (1999) showed that in the Nile tilapia, induction of hyperthyroidism by feeding 
the animals with T3-supplemented food (12 ppm) for 11 days resulted in a prominent 
decrease in hepatic D2 activity, where as hepatic D3 activity increased. However, neither 
brain nor gill D3 activity was affected, nor was kidney D1 activity. On the other hand 
induction of hypothyroidism by providing fish food containing 0.2% methimazole for 11 
days increased liver type II deiodinase (D2) with no changes in kidney type I deiodinase 
(D1), and resulted in a significant decrease in brain, gill and liver type III deiodinase 
(D3).  Other  studies  demonstrated  that  the  hepatic  D1  activity,  as  well  as  D1  mRNA 
expression, is up regulated in hypothyroid tilapia (Van der Geyten et al 2001). 
Numerous  chemicals  can  modify  vertebrate  thyroid  function.  They  range  from 
complex  synthetic  halogenated  or  phosphorylated  hydrocarbons  to  simple  cations  or 
anions  (Brown  et  al  2004).  A  study  done  on  thirty  eight  dogs  that  were  treated  for 
orthopedic disorders were given etodolac (10 to 13.3 mg/kg, orally, once daily) for 14 
days, serum T4 concentration decreased significantly after etodolac administration with 
increased canine thyroid stimulating hormone (cTSH). Serum free T4 concentration was 
not significantly affected (Ness et al 2003). PGs are known to influence a wide range of 
physiological processes by enhancing the release of hormones and altering the sensitivity 
of target organs (Lands 1991). Studies on mammals further showed that PGs enhanced 
the response of thyroid tissue to TSH, resulting in higher T3 and T4 levels (Lands 1991). 
Basal levels of T3 were also significantly reduced in tilapia after acetyl salicylic acid (ASA) AACL Bioflux, 2011, Volume 4, Issue 5. 
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treatment,  suggesting  that  PGs  have  a  similar  regulatory  function  (Van  Anholt  et  al 
2003). 
According to our literature review we propose that etodolac and etoricoxib could 
induce a hypothyroid state in tilapia. Since the thyroid cascade may respond indirectly 
and it has considerable capacity to compensate for abuses that otherwise would disrupt 
thyroid  hormone  homeostasis,  it  up  regulates  peripheral  deiodinase  enzymes  as 
mentioned previously. In addition inhibition of plasma protein binding has increased f T4 
and f T3. Less than 1% of plasma total T4 (TT4) is free (FT4) with 99% reversibly bound 
to  plasma  proteins.  Plasma  FT4  has  a  strong  negative feedback action on the brain–
pituitary–thyroid axis aggravating the hypothyroid state. Although the proportion of total 
T3 (TT3) that is free in plasma (FT3) is usually less than that for T4, the T3 binds also to 
some plasma proteins that bind T4. It is also worth to mention that the thyroid axis 
(TRH,  TSH,  and  T3)  stimulates  both  synthesis  and  release  of  GH  in  tilapia,  thus 
interfering with this axis could indirectly alter GH secretion (Melamed et al 1999). 
Results showed no increase or decrease of growth in mixed population adult Nile 
tilapia treated with 0.5% etodolac and 0.5% etoricoxib. This result reflects the fact that 
growth is regulated by several controls including differences in levels of both sex-related 
hormones and metabolic hormones, with growth hormone having a pivotal role. Thyroid 
hormones and gonadal steroids are important, in particular during the initial phase of 
sexual  maturation  and  development  (Brown  et  al  2004).  Thyroid  hormones  assist  in 
control of osmoregulation, metabolism, somatic growth, development, and posthatching 
metamorphosis (Janz & Weber 2000). Metamorphosis in flounders Paralichthys olivaceus 
(Temminck  &  Schlegel,  1846)  and  P.  dentatus  (Linnaeus,  1766),  and  flatfish 
Hippoglossus  hippoglossus  (Linnaeus,  1758)  is  associated  with  a  dramatic  spike  in 
thyroxin (T4) concentrations (Tagawa et al 1990; Schreiber & Specker 1999; Saele et al 
2006).  These  results  support  our  hypothesis  that  COX-inhibitors  could  modulate 
aromatase  enzyme  during  the  crucial  period  of  sexual  differentiation  as  we  discussed 
previously. In addition deiodination activity in fish is responsive to many environmental 
and  physiological  conditions  (e.g.,  food  quantity,  food  quality,  pH,  salinity,  turbidity) 
(Eales et al 1999). Tilapia kept in partially closed systems and fed artificial diets have 
been reported to have a decreased growth after a certain period of time. This may be due 
to the fact that tilapia needs a continuous supply of their natural food or because of a 
build-up of growth inhibiting factors in the system (Jackson et al 1982). 
The increase in gastrointestinal blood flow (GBF) after the ingestion of a normal 
sized meal ranges from around 70% in the sea bass (Axelsson et al 2002) to over 150% 
in the sea bass and the rainbow trout Oncorhynchus mykiss (Walbaum, 1792) according 
to Dupont-Prinet et al (2009) and Grans et al (2009). The postprandial increase in GBF 
will depend on both the decrease in resistance of the GI vasculature, i.e. the hyperemia, 
and how much blood that is available to the GI tract, either by an increase in cardiac 
output or a redistribution of blood. There is a shift in the amount of CO reaching the GI 
vasculature  in  fish,  which  is  mediated  via  a  decrease  in  the  resistance  of  the  GI 
vasculature and a maintained or increased resistance of other systemic vascular beds. 
After  the  meal  has  been  digested  i.e.  enzymatically  broken  down  into  smaller 
components by carbohydrases, lipases and proteases, it is likely that these hydrolyzed 
products  that  induce  the  subsequent  GI  hyperemia.  The  mechanical  distension  of  the 
stomach elicits an increased adrenergic tone on the systemic vasculature, producing a 
vasoconstriction in the systemic circulation including the GI portion, and a subsequent 
increase in dorsal aortic pressure. This leads to either a redistribution of blood flow from 
the systemic circulation or a larger fraction of the cardiac output reaching the GI tract in 
the event that cardiac output increases. This pressor response increases the driving force 
for  the  perfusion  of  the  GI  vasculature  when  chemical  stimuli  (hyperemia)  induce  a 
decrease  in  the  resistance  of  the  GI  vasculature  mediated  via  hormones  like 
cholecystokinin (CCK) (Seth et al 2010). NSAIDs may enhance the proteolytic activity of 
the  gut  by increasing  proteases  activity,  thus  accelerating  the  hyperemia  event  (Rust 
2002). 
It is well known that prostaglandins have diverse effects in fish circulation as PGE2 
causes a reduction in cardiac output with a decrease in systemic resistance and increase AACL Bioflux, 2011, Volume 4, Issue 5. 
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in gills vascular resistance. It also reduces dorsal aortic blood pressure (Stensløkken et al 
2002). Thus, blocking prostaglandins synthesis abolishes their effect mentioned on the 
heart. Further more acidic water from, accumulation of these drugs in a closed system 
could  act  as  a  stressor  that  activate  catecholamine  release  which  have  additional 
stimulatory effects on cardiac output (Randall & Perry 1992). 
  
Mortality  vs  toxicity.  The  different  concentrations  affected  the  growth  rate  in  a 
concentration dependent manner (Figure 2). This appears with the weight of fish treated 
with etodolac and etoricoxib compared to standard. The highest growth rate was in the 
aquarium treated with 2% etodolac, followed by 1% etodolac. The 1% etoricoxib showed 
a decreased growth rate compared to standard which could indicates a toxic potential of 
etoricoxib toward fish at this concentration. In addition growth rate with 0.5% etodolac 
(0.131 and 0.136) was higher than with increasing concentrations of etodolac that show 
growth rate of 0.05 with 1% etodolac and 0.107 with 2% etodolac, respectively. These 
facts could be considered as sign of toxicity. Gills alterations may interfere with normal 
respiratory functions and renal changes might lead to impaired osmoregulation (Evans et 
al 2005). Since etoricoxib is selective COX-2 inhibitor more pronounced effect is expected 
to be seen on osmoregulation in tilapia, but, for most studies, fish from domesticated 
stocks  have  been  used,  and  such  fish  may  have  a  blunted  stress  response  when 
compared with wild-type strains of the same pecies (Woodward & Strange 1987). 
Figure 2. Growth rate of mixed population Nile tilapia treated with 1% etodolac, 1% etoricoxib, 2% 
etodolac mixed with food at age of 8 days (eto1% - etoricoxib 1%, etd1% - etodolac 1%, etd2% - 
etodolac 2%). 
  
In  reference  to  Figure  3,  there  were  no  differences  in  mortality  rates  between  0.5% 
etodolac  and  0.5%  etoricoxib  treatments,  but  survival  rate  96.6%  and  90%  was 
improved compared to control (86.6%, and 83.3%, respectively) during the experimental 
feeding. Higher mortalities were shown as concentrations increase with 1% etoricoxib, 
1%  etodolac and 2% etodolac treatments (Figure 4). Improved survival could reflect the 
anti  inflammatory  effect  of  COXs  inhibitors.  One  could  expect  that  use  of  NSAIDs  is 
associated with lower levels of inflammatory markers (Il’yasova et al 2005). Mortality 
rates for 0.5% etodolac and 0.5% etoricoxib were comparable to 0.5% ibuprofen and 
significantly  lower  than  0.5%  diclofenac  reported  in  a  previous  study  (Al-Qutob  & 
Nashashibi 2009).  
So far, there are no data available on the chronic toxicity of etodolac and etoricoxib 
to fish. Previous studies with ibuprofen showed its toxicity on aquatic crustacean Daphnia 
magna Straus, 1820, and the mollusk Planorbis carinatis Müller, 1774 which had been 
reported to be in mgL
-1 range (Pounds et al 2008). Other study carried on adult Japanese 
medaka O. latipes showed that exposure to nominal concentrations of ibuprofen in the 
range  of  (1-100ugL
-1)  for  6  weeks  altered  reproduction  with  no  evident  pathological AACL Bioflux, 2011, Volume 4, Issue 5. 
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damage in the gills, liver and kidneys of fish from the highest exposure group (Flippin et 
al 2007). 
Figure 3. Survival and mortality rates during treatment with 0.5% etodolac and 0.5% etoricoxib. 
 
Figure 4. Survival and mortality rates during treatment with different concentrations of etoricoxib 
1%, etodolac 1%, and etodolac 2%. 
 
Determination of etoricoxib in fish feces. In reference to Figure 5 the retention time 
of etoricoxib 100 ppm injected sample was 4.18 min. However, the feces sample injected 
to HPLC system, showed no peak for etoricoxib (Figure 6). As a result all etoricoxib is 
metabolized and the metabolites are excreted with no unchanged fraction of the drug. 
This  is  in  contrast  to  humans,  where  minor  fraction  of  the  dose  (<1%)  is  excreted 
unchanged (Rodrigues et al 2003).  
In  healthy  male  subjects,  etoricoxib  is  well  absorbed,  with  an  absolute  oral 
bioavailability of 83% and a low clearance with a t1/2 of 24.8h. In addition, etoricoxib is 
metabolized extensively (more than 98%) via 6-methyl hydroxylation (major) and 1-N-
oxidation.  
These  metabolites  are  either  excreted  directly,  or  are  metabolized  further  to 
secondary metabolites that are also excreted largely by urine (70%) and  by feces (20%) 
with less than 2% recovered unchanged as etoricoxib. The 6-carboxylic acid derivative of 
etoricoxib is the major metabolite observed the oxidative metabolism is catalyzed by 
multiple P450s in the presence of NADPH-fortified human liver microsomes, with CYP3A4 
playing an important role (60%), and the remainder of the activity shared more or less 
equally among other P450s (e.g., CYP2C9, 2D6, 1A2, and 2C19) (Rodrigues et al 2003).  
Because of the low levels in plasma and weak COX-2 activity, the metabolites of 
etoricoxib  are  unlikely  to  contribute  to  the  inhibition of COX-2 in vivo (Chauret et al 
2001). Moreover, the involvement of multiple P450s, and the low first pass effect, as the 
hepatic  extraction is calculated to be 0.04, with negligible gut first pass metabolism, AACL Bioflux, 2011, Volume 4, Issue 5. 
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effectively  minimizes  the  potential  for  significant  drug  interactions  with  potent  P450 
inhibitors (Kassahun et al 2001). 
Figure 5. HPLC result from etoricoxib 100 ppm injected sample. 
Figure 6. HPLC result from tilapia feces injected sample showing no etoricoxib peaks. 
 
We do not know if it’s, low first pass effect, with high bioavailability and low hepatic 
extraction  ratio,  contributes  to  its  long  t1/2=28.6h,  renders  it  available  to  systemic 
circulation and increase its toxicity towards fish. Unrecovered of unchanged drug from 
feces, could indicate that etoricoxib was either extensively metabolized by liver or some 
of the drug have undergone enterohepatic circulation (Figure 6). While renal excretion is 
the  most  important  route  for  final  elimination  of  NSAIDs,  nearly  all  undergo  varying 
degrees  of  biliary  excretion  and  reabsorption  (enterohepatic  circulation).  In  fact,  the 
degree  of  lower  gastrointestinal  tract  irritation  correlates  with  the  amount  of 
enterohepatic  circulation.  Far,  there  is  no  report  on  etoricoxib  and  enterohepatic 
circulation (Brune et al 2010). 
 
Conclusions. The highest growth rate was with 2% etodolac, followed by 1% etodolac, 
but optimum dose with lower mortality (3.4% and 10%) was with 0.5% etodolac, and 
0.5% etoricoxib which show SGR (%) of 4.93 and 4.64, respectively. The 1% etoricoxib 
showed  a  decreased  growth  rate  compared  to  standard  which  could  indicates a toxic 
potential of etoricoxib toward fish at this concentration. The 0.5% etodolac and 0.5% 
etoricoxib could be the optimum dose for improving growth rate with lower mortality. 
Subsequent field investigations in normal aquaculture bonds are needed to confirm these 
results  in  larger  population,  using  different  classes  of  COXs-inhibitors  at  different 
concentrations. Etoricoxib have been metabolized in the fish body with no change in the 
movement, appetite for food or any other differences in compared with the fish treated 
with both drugs compared to control during the experimental period. It is clear evident 
from mortality rates that even administration of high concentrations of these drugs was 
well tolerated by fish. Since there is a possibility to undergo enterohepatic circulation fish 
living downstream the wastewater treatment plants and which are chronically exposed to 
the drug may accumulate the drug and its metabolites in bile. Although most of these 
pharmaceuticals undergo extensive dilution and degradation during sewage treatment, 
the  potential  effects  of  COX  inhibitors  on  physiologic  functions  in  fish  will  require 
attention,  particularly  as  human  longevity  increases  requiring  greater  use  of  anti-AACL Bioflux, 2011, Volume 4, Issue 5. 
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inflammatory drugs. Thus it should be investigated further for their ability to alter fish 
thyroidal status, and reproduction chronically. 
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